Pfizer Says Sutent Will Remain the Standard for Cancer
This article is for subscribers only.
Pfizer Inc. said its Sutent pill will continue to be the standard treatment for renal cell carcinoma after GlaxoSmithKline Plc said its competing Votrient drug showed similar effectiveness with fewer side effects.
Patients taking Sutent survived an average of 9.5 months without the disease progressing, compared with 8.4 months for those on Votrient, in a study of 1,100 patients, London-based Glaxo said yesterday. Side effects such as fatigue and skin sores occurred with less frequency for Votrient.